Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Multiple myeloma is a haematologic malignancy of the bone marrow with an increasing incidence, primarily affecting an elderly and frail population. It benefits from innovative treatments that have been shown to extend patient survival. However, 2% of patients die from infections during the first year of treatment, despite the availability of prophylactic treatments. Thanks to their new skills, advanced practice nurses could play a new role in this care. We conducted a prospective quantitative multicenter study in three French hospitals. Over a two-month period, questionnaires were administered to patients with multiple myeloma in the first year of treatment, followed up in three hospitals. The questionnaire consisted of open and closed questions on the themes of infectious risk, antibiotic prophylaxis and vaccination. A total of 60 participants completed the questionnaire. The results show a lack of knowledge on the part of patients of the risk of infection, the symptoms that need to be reported, and the absence of a specific pathway for effective management. There was also a lack of awareness of the names of recommended prophylactic treatments and their usefulness. Finally, the vaccination strategy is generally appropriate, except for pneumococcal vaccination, which is less systematically applied. This study provides valuable insights into the role that APN could play in therapeutic education, in particular by improving patients' knowledge of therapies, monitoring vaccinations, coordinating care pathways and acting as a resource for patients and the healthcare team.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2025.06.008DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
12
infectious risk
8
patients multiple
8
advanced practice
8
year treatment
8
prophylactic treatments
8
patients
5
[representation infectious
4
risk patients
4
myeloma multicentric
4

Similar Publications

Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.

Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.

Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.

View Article and Find Full Text PDF

Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs), which vary in efficacy, toxicity, and accessibility. To compare the efficacy and safety of BCMA-directed CAR-T therapies and BiTEs in R/R MM through a systematic review and meta-analysis.

View Article and Find Full Text PDF

Background: Light chain multiple myeloma (LCMM) is a malignant hematological disease characterized by bone marrow infiltration by tumor plasma cells and the secretion of monoclonal free light chains (κ or λ). It is often di-agnosed through hypogammaglobulinemia detected by serum protein electrophoresis, followed by immunotyping showing a monoclonal band in free light chains. However, the structure of monoclonal light chains can sometimes complicate laboratory findings.

View Article and Find Full Text PDF